Technical Data
Epidermal Growth Factor Receptor (erbB, EGFR)
EGFR is type I receptor tyrosine kinase with sequence homology to erbB-1, -2, -3 -4 or HER-1, -2,-3 -4. It binds to Epidermal Growth Factor (EGF), Transforming Growth Factor-a (TGF-a), Heparin-binding EGF (HB-EGF), amphiregulin, betacellulin and epiregulin. EGFR is overexpressed in tumors of breast, brain, bladder, lung, gastric, head and neck, esophagus, cervix, vulva, ovary, and endometrium. It is predominantly present in squamous cell carcinomas.

Suitable for use in Flow Cytometry, Immunoprecipitation and Immunohistochemistry. Not suitable for use in Western Blot. Other applications not tested.

Recommended Dilutions:
Flow Cytometry: 1:50-1:100. Use 10ul to label 10e6 cells in 100ul.
Immunohistochemistry: Frozen and paraffin sections
Optimal dilutions to be determined by the researcher.

Recommended Secondary Reagent:
I1904-49H: IgG, F(ab')2, H&L X-Adsorbed (HRP) RbxRt
I1904-47H: IgG, H&L (HRP) Pab GtxRt

Positive Control:
Breast carcinoma

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
MabIgG2a3H2090Highly Purified
200ug-20CBlue IceHumanRat
Extracellular domain of human EGF-receptor from head and neck carcinoma.
Purified by Ion Exchange chromatography.
Supplied as a liquid in PBS, pH 7.4, 0.09% sodium azide.
Recognizes the human epidermal growth factor receptor (EGF-R), which is overexpressed in a high proportion of breast cancer cells and in a range of other carcinomas. High level expression of EGFR is often associated with advanced disease and poor prognosis. Binds to epitope B from EGFR and has an affinity of 6.7x10e-9M.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Lottaz, C. et al. (2010) Cancer Res. 70: 2030-40. 2. Modjtahedi, H. et al. (1993). Cell Biophs. 22(1-3):129-46. 3. Modjtahedi, H. et al. (2012) Br J Cancer. 106: 883888. 4. Gilcrease, M.Z. et al. (2009) J Exp Clin Cancer Res. 28: 67. 5. Lottaz, C. et al. (2010) Cancer Res. 70: 2030-40.